[1]
Baum, M.; Budzar, A.U.; Cuzick, J.; Forbes, J.; Houghton, J.H.; Klijn, J.G.; Sahmoud, T. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet, 2002, 359(9324), 2131-2139.
[2]
Nicholson, R.I.; Gee, J.M. Oestrogen and growth factor cross-talk and endocrine insensitivity and acquired resistance in breast cancer. Br. J. Cancer, 2000, 82(3), 501-513.
[3]
Menéndez, J.A.; Mehmi, I.; Griggs, D.W.; Lupu, R. The angiogenic factor CYR61 in breast cancer: molecular pathology and therapeutic perspectives. Endocr. Relat. Cancer, 2003, 10(2), 141-152.
[4]
Lau, L.F.; Lam, S.C. The CCN family of angiogenic regulators: the integrin connection. Exp. Cell Res., 1999, 248(1), 44-57.
[5]
Perbal, B. The CCN family of genes: a brief history. Mol. Pathol., 2001, 54(2), 103-104.
[6]
Brigstock, D.R. The connective tissue growth factor/cysteine-rich 61/nephroblastoma overexpressed (CCN) family. Endocr. Rev., 1999, 20(2), 189-206.
[7]
Tsai, M.S.; Hornby, A.E.; Lakins, J.; Lupu, R. Expression and function of CYR61, an angiogenic factor, in breast cancer cell lines and tumor biopsies. Cancer Res., 2000, 60(20), 5603-5607.
[8]
Xie, D.; Nakachi, K.; Wang, H.; Elashoff, R.; Koeffler, H.P. Elevated levels of connective tissue growth factor, WISP-1, and CYR61 in primary breast cancers associated with more advanced features. Cancer Res., 2001, 61(24), 8917-8923.
[9]
Saglam, O.; Dai, F.; Husain, S.; Zhan, Y.; Toruner, G.; Haines, G.K. III Matricellular protein CCN1 (CYR61) expression is associated with high-grade ductal carcinoma in situ. Hum. Pathol., 2014, 45(6), 1269-1275.
[10]
OKelly. J.; Chung, A.; Lemp, N.; Chumakova, K.; Yin, D.; Wang, H.J.; Said, J.; Gui, D.; Miller, C.W.; Karlan, B.Y.; Koeffler, H.P. Functional domains of CCN1 (Cyr61) regulate breast cancer progression. Int. J. Oncol., 2008, 33(1), 59-67.
[11]
Tsai, M.S.; Bogart, D.F.; Castañeda, J.M.; Li, P.; Lupu, R. Cyr61 promotes breast tumorigenesis and cancer progression. Oncogene, 2002, 21(53), 8178-8185.
[12]
Lin, J.; Huo, R.; Wang, L.; Zhou, Z.; Sun, Y.; Shen, B.; Wang, R.; Li, N. A novel anti-Cyr61 antibody inhibits breast cancer growth and metastasis in vivo. Cancer Immunol. Immunother., 2012, 61(5), 677-687.
[13]
Lai, D.; Ho, K.C.; Hao, Y.; Yang, X. Taxol resistance in breast cancer cells is mediated by the hippo pathway component TAZ and its downstream transcriptional targets Cyr61 and CTGF. Cancer Res., 2011, 71(7), 2728-2738.
[14]
Cheng, J.; Lei, L.; Xu, J.; Sun, Y.; Zhang, Y.; Wang, X.; Pan, L.; Shao, Z.; Zhang, Y.; Liu, G. 18F-fluoromisonidazole PET/CT: a potential tool for predicting primary endocrine therapy resistance in breast cancer. J. Nucl. Med., 2013, 54(3), 333-340.
[15]
Harvey, J.M.; Clark, G.M.; Osborne, C.K.; Allred, D.C. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J. Clin. Oncol., 1999, 17(5), 1474-1481.
[16]
Wolff, A.C.; Hammond, M.E.; Hicks, D.G.; Dowsett, M.; McShane, L.M.; Allison, K.H.; Allred, D.C.; Bartlett, J.M.; Bilous, M.; Fitzgibbons, P.; Hanna, W.; Jenkins, R.B.; Mangu, P.B.; Paik, S.; Perez, E.A.; Press, M.F.; Spears, P.A.; Vance, G.H.; Viale, G.; Hayes, D.F. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J. Clin. Oncol., 2013, 31(31), 3997-4013.
[17]
Yang, G.P.; Lau, L.F. Cyr61, product of a growth factor-inducible immediate early gene, is associated with the extracellular matrix and the cell surface. Cell Growth Differ., 1991, 2(7), 351-357.
[18]
Sampath, D.; Winneker, R.C.; Zhang, Z. Cyr61, a member of the CCN family, is required for MCF-7 cell proliferation: regulation by 17beta-estradiol and overexpression in human breast cancer. Endocrinology, 2001, 142(6), 2540-2548.
[19]
Xie, D.; Miller, C.W. OKelly, J.; Nakachi, K.; Sakashita, A.; Said, J.W.; Gornbein, J.; Koeffler, H.P. Breast cancer. Cyr61 is overexpressed, estrogen-inducible, and associated with more advanced disease. J. Biol. Chem., 2001, 276(17), 14187-14194.
26
6